CDH17 and neoplasm: The most exciting clinical application of [89Zr]Zr-DFO-D2101 may be as a companion theranostic imaging agent for CDH17-targeted therapies, as the non-invasive nature of immunoPET offers distinct advantages over extant methods (i.e., biopsy) for the annotation of CDH17 expression by tumor tissue.